Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

17 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Etanercept: an overview of dermatologic adverse events.
Lecluse LL, Dowlatshahi EA, Limpens CE, de Rie MA, Bos JD, Spuls PI. Lecluse LL, et al. Arch Dermatol. 2011 Jan;147(1):79-94. doi: 10.1001/archdermatol.2010.410. Arch Dermatol. 2011. PMID: 21242398 Review.
Switching from etanercept to adalimumab is effective and safe: results in 30 patients with psoriasis with primary failure, secondary failure or intolerance to etanercept.
Van Lümig PP, Lecluse LL, Driessen RJ, Spuls PI, Boezeman JB, van de Kerkhof PC, De Jong EM. Van Lümig PP, et al. Among authors: lecluse ll. Br J Dermatol. 2010 Oct;163(4):838-46. doi: 10.1111/j.1365-2133.2010.09950.x. Epub 2010 Sep 2. Br J Dermatol. 2010. PMID: 20649798 Clinical Trial.
International eDelphi Study to Reach Consensus on the Methotrexate Dosing Regimen in Patients With Psoriasis.
van Huizen AM, Menting SP, Gyulai R, Iversen L, van der Kraaij GE, Middelkamp-Hup MA, Warren RB, Spuls PI; SPIN MTX Consensus Survey Study Group; Schejtman AA, Egeberg A, Firooz A, Kumar AS, Oakley A, Foulkes A, Ramos AMC, Fougerousse AC, Carija A, Akman-Karakas A, Horváth B, Fábos B, Matlock BH, Claréus BW, Castro C, Ferrándiz C, Correa CC, Marchesi C, Goujon C, Gonzalez C, Maldonado-García C, Hong CH, Griffiths CEM, Vestergaard C, Echeverría CM, de la Cruz C, Conrad C, Törocsik D, Drvar DL, Balak D, Jullien D, Appelen D, Kim DH, de Jong EMGJ, El Gamal E, Laffitte E, Mahé E, Sonkoly E, Colombo EP, Vilarrasa E, Willaert F, Novoa FD, Handjani F, Valenzuela F, Vílchez-Márquez F, Gonzalez GO, Krisztián G, Damiani G, Krnjevic-Pezic G, Pellerano G, Carretero G, Hunter HJA, Riad H, Oon HH, Boonen HPJ, Moussa IO, García-Doval I, Csányi I, Brajac I, Turchin I, Grozdev I, Weinberg JM, Nicolopoulos J, Wells J, Lambert JLW, Ingram JR, Prinz JC, de Souza Sittart JA, Sanchez JL, Hsiao JP, Castro-Ayarza JR, Maul JT, van den Reek JMPA, Trcko K, Barber K, Reich K, Gebauer KA, Khobzei K, Maul LV, Massari LP, Fardet L, le Cleach L, Misery L, Chandrashekar L, Muresanu LI, Lecluse L, Skov L, Frez ML,… See abstract for full author list ➔ van Huizen AM, et al. JAMA Dermatol. 2022 May 1;158(5):561-572. doi: 10.1001/jamadermatol.2022.0434. JAMA Dermatol. 2022. PMID: 35353175
The correlation of clinical efficacy, serum trough levels and antidrug antibodies in ustekinumab-treated patients with psoriasis in a clinical-practice setting.
Menting SP, van den Reek JM, Baerveldt EM, de Jong EM, Prens EP, Lecluse LL, Wolbink GJ, Van der Kleij D, Spuls PI, Rispens T. Menting SP, et al. Among authors: lecluse ll. Br J Dermatol. 2015 Sep;173(3):855-7. doi: 10.1111/bjd.13834. Epub 2015 Aug 2. Br J Dermatol. 2015. PMID: 25865153 No abstract available.
17 results